Alec Stranahan
BofA Securities, Research Division

Welcome to day 2 of the 2026 Bank of America Healthcare Conference. My name is Alec Stranahan. I cover biotech at Bank of America, and welcome to this session with Nuvation Bio.

Very pleased to introduce, to my left, David Hung, Chief Executive Officer; and Philippe Sauvage, the Chief Financial Officer of Nuvation. Thanks for being here, guys.

David Hung
Founder, President, CEO & Chairman

Thanks for having us.

Alec Stranahan
BofA Securities, Research Division

Yes. Looking forward to our conversation here.

Alec Stranahan
BofA Securities, Research Division

I guess maybe just jumping right in. You've reported 3 consecutive quarters of accelerating and growing new patient starts. Net product revenues beginning to catch up with that. I guess how has the launch been tracking with sort of your expectations? And what are sort of the near-term catalysts to look out for, for continuing the growth?

David Hung
Founder, President, CEO & Chairman

I think the launch has gone very well. We've said that if you look at our new patient starts, so far in our launch, we've had more new patient starts than both previous TKIs combined. So we're pretty excited about that.

The real name of the game is to move to the first-line setting. And I think this is something that's maybe an unusual concept in oncology because very few oncology drugs have durations of response in the range of what we've seen with IBTROZI. So we mentioned previously, having a DOR of over 4 years is highly unusual. In